Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BFM Regimen Plus TKI in Adult Ph+ ALL
NCT04845035Phase 2Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, ponatinib in acute lymphoblastic leukemia (ALL), sponsored by University of Michigan Rogel Cancer Center. Planned start Jan 2024; status: withdrawn.
02
Drugs
dasatinibponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04845035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04845035.